<?xml version="1.0"?>
<metadata xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/"><dc:title>A rapid method for determination of rosuvastatin in blood plasma with supported liquid extraction</dc:title><dc:creator>Dermota,	Tjaša	(Avtor)
	</dc:creator><dc:creator>Božič Mijovski,	Mojca	(Avtor)
	</dc:creator><dc:creator>Trontelj,	Jurij	(Avtor)
	</dc:creator><dc:subject>supported liquid extraction</dc:subject><dc:subject>liquid-liquid extraction</dc:subject><dc:subject>rosuvastatin</dc:subject><dc:subject>LC-MS/MS</dc:subject><dc:subject>myocardial infarction</dc:subject><dc:subject>solid-phase extraction</dc:subject><dc:subject>blood plasma</dc:subject><dc:description>Introduction: Accurate measurement of rosuvastatin in plasma is critical for effective patient management and treatment monitoring following myocardial infarction (MI). Expensive solid-phase extraction (SPE) and timeconsuming liquid-liquid extraction (LLE) have been established for quantifying rosuvastatin. Supported liquid extraction (SLE) could offer a rapid, cost-effective alternative. Objectives: This study aimed to develop and validate a rapid, cost-effective, accurate, and precise method for quantifying rosuvastatin in high-dose plasma samples from patients following MI. Methods: Rosuvastatin was extracted from EDTA plasma using SLE and quantified with LC-MS/MS with positive electrospray ionization. The method was validated according to ICH M10 guidelines, focusing on selectivity, matrix effect, accuracy, precision, linearity, and carryover. Rosuvastatin-D6 was used as an internal standard. Additionally, thirty plasma samples from patients on high-dose rosuvastatin therapy (20 or 40 mg/day) following MI were analyzed by both LLE and SLE methods and compared. Results: The method was successfully validated, demonstrating linearity across a range of 0.1 ng/mL to 50 ng/mL. Compared to the LLE method, SLE achieved superior extraction recovery (96.3 % vs. 60 %) and precision (RSD: 11.9 % vs. 13.6 %) at 0.3 ng/mL rosuvastatin, with a lower absolute matrix effect (12.7 % vs.-36.7 %). Accuracy was comparable (109.3 % vs. 92.8 %). Although SLE involves higher initial costs, it significantly enhances throughput, reduces solvent usage, and minimizes contamination and equipment wear. Conclusion: This study validates SLE as a superior method for quantifying rosuvastatin in plasma, outperforming LLE in recovery, reproducibility, and automation. SLE offers greater accuracy and reliability, making it ideal for high-throughput applications.</dc:description><dc:date>2025</dc:date><dc:date>2025-11-24 15:32:42</dc:date><dc:type>Neznano</dc:type><dc:identifier>24301</dc:identifier><dc:identifier>UDK: 543.544:61</dc:identifier><dc:identifier>ISSN pri članku: 2667-145X</dc:identifier><dc:identifier>DOI: 10.1016/j.jmsacl.2025.04.003</dc:identifier><dc:identifier>COBISS_ID: 245998595</dc:identifier><dc:language>sl</dc:language></metadata>
